Rezdiffra (Resmetirom) Cost in Missouri 2026

What Does Rezdiffra Actually Cost in Missouri?

Rezdiffra's wholesale acquisition cost (WAC) set by Madrigal Pharmaceuticals is $3,500 per month, or roughly $42,000 per year. That figure applies uniformly across Missouri retail pharmacies in 2026, because no generic resmetirom exists and no biosimilar pathway applies to a small-molecule thyroid hormone receptor beta (THR-beta) agonist. Cash-pay patients at Missouri chains such as CVS, Walgreens, and Schnucks Pharmacy will see prices anchored at or near that WAC. Rezdiffra FDA prescribing information confirms the 80 mg and 100 mg tablet presentations that drive this pricing.

Why the Price Is So High

Resmetirom is the first and only FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (stages F2 and F3). Madrigal Pharmaceuticals spent over a decade and more than $1 billion in development costs before the March 2024 accelerated approval. Orphan-drug economics, a single manufacturer, and no approved competitor keep the WAC at $3,500 monthly. The FDA accelerated approval framework requires a confirmatory trial (MAESTRO-NASH outcomes, ongoing), which adds post-market cost that manufacturers typically price into launch WAC.

Price vs. Cost-Effectiveness Estimates

An Institute for Clinical and Economic Review (ICER) draft report aligned with the MAESTRO-NASH results estimated a cost-effectiveness threshold suggesting prices between $12,000 and $24,000 annually could be within commonly accepted value benchmarks. At $42,000 per year, Rezdiffra exceeds that range for many payers, which directly explains why Missouri Medicaid and many commercial formularies place it on a non-preferred or non-covered tier. MAESTRO-NASH (N=966) demonstrated that resmetirom 100 mg produced MASH resolution in 25.9% of patients vs. 9.7% placebo (P<0.001) and fibrosis improvement in 24.2% vs. 14.2% placebo (P<0.001) at 52 weeks. [1]

Missouri Medicaid Coverage for Rezdiffra

Missouri Medicaid (MO HealthNet) does not cover Rezdiffra for the MASH indication as of 2026. Coverage is conditionally available only when resmetirom is prescribed for type 2 diabetes (T2D) management, a narrow off-label use that most hepatologists will not be pursuing given the drug's approved indication. Missouri's Medicaid pharmacy benefit follows a preferred drug list (PDL) model; Rezdiffra does not appear on the MO HealthNet PDL for liver disease.

Prior Authorization Requirements Under MO HealthNet

Even for T2D-related prescribing, MO HealthNet requires a prior authorization (PA) demonstrating that the patient has failed at least two first-line agents, has a confirmed MASH diagnosis via liver biopsy or FibroScan with controlled attenuation parameter (CAP), and has a body mass index (BMI) consistent with metabolic syndrome. Providers submitting a PA for a MASH-only indication will receive an automatic denial under current 2026 MO HealthNet criteria.

Medicaid Expansion and Future Coverage Prospects

Missouri expanded Medicaid under the Affordable Care Act effective October 2021. Roughly 275,000 additional Missourians gained coverage through that expansion. [2] Despite expansion, specialty drug coverage policy for novel hepatology agents has lagged. The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance on MASH explicitly endorses pharmacotherapy for F2, F3 fibrosis, which may support future PA appeals, but MO HealthNet has not incorporated that language into its 2026 PDL criteria as of this article's review date. [3]

Commercial Insurance Coverage in Missouri

Most large commercial plans operating in Missouri, including Anthem Blue Cross Blue Shield of Missouri, Cigna, Aetna, and UnitedHealthcare, place Rezdiffra on Tier 4 or Tier 5 specialty formulary tiers. That means out-of-pocket costs after PA approval commonly range from $500 to $1,200 per month depending on your plan's specialty cost-sharing structure. Before the savings card is applied, a Missouri patient on a 30% specialty coinsurance plan would owe $1,050 monthly.

Standard Prior Authorization Criteria for Commercial Plans

Commercial PA criteria in Missouri generally require all of the following:

• Confirmed MASH diagnosis (liver biopsy or validated noninvasive test showing fibrosis stage F2 or F3)
• BMI <40 kg/m2 or documented metabolic risk factors
• Prescriber is a gastroenterologist, hepatologist, or internist with liver disease experience
• Patient is not pregnant or planning pregnancy (resmetirom is FDA Pregnancy Category X equivalent; the label carries a contraindication in pregnancy) [4]
• No concurrent use of moderate-to-strong CYP2C8 inhibitors without documented justification

The FDA label's contraindication in pregnancy is based on animal reproductive toxicity data and carries a REMS-adjacent warning. [4] Prescribers in Missouri should document pregnancy status in every PA submission to avoid automatic denial.

Step Therapy and Appeals

Several Missouri commercial plans require documented failure of lifestyle intervention (minimum 6-month diet and exercise program with documented weight loss <10% of body weight) before approving Rezdiffra. If your first PA is denied, a peer-to-peer review with the plan's medical director is the fastest reversal route. The American Gastroenterological Association (AGA) Clinical Practice Guideline on MASH pharmacotherapy provides strong-recommendation language supporting resmetirom in F2, F3 patients that can be cited verbatim in appeals. [5]

Madrigal Pharmaceuticals Savings Card: How It Works in Missouri

Madrigal offers the Rezdiffra Access Program savings card directly on its website. Commercially insured Missouri patients who meet eligibility criteria may pay as little as $0 per month in copays. The card covers the gap between what insurance pays and what the patient owes, up to a defined annual maximum benefit.

Eligibility Rules

• Must have commercial insurance (not Medicaid, Medicare, or any federally funded program)
• Missouri residents qualify geographically; no state-specific exclusion exists
• Income verification is not required for the commercial copay card
• Patients enrolled in a Medicare Advantage plan are not eligible, because federal anti-kickback statute prohibits manufacturer copay assistance for Medicare beneficiaries

Patient Assistance Program for Uninsured Patients

For uninsured Missouri patients or those whose commercial insurance denies coverage, Madrigal's patient assistance program (PAP) provides Rezdiffra at no cost to qualifying low-income patients. The income threshold generally follows 400% of the federal poverty level (FPL). A Missouri household of two earning under approximately $79,480 annually (2026 FPL estimates) would likely qualify. Enrollment requires a completed application, income documentation, and prescriber signature. Applications are processed within 10 to 15 business days. Madrigal's REMS program for reproductive risk does not change PAP eligibility.

Is Compounded Resmetirom Legal in Missouri?

Compounded resmetirom is legally available through 503A compounding pharmacies in Missouri. 503A pharmacies operate under state pharmacy board oversight and federal Food, Drug, and Cosmetic Act Section 503A, which permits patient-specific compounding when a valid prescriber-patient relationship exists. [6]

503A vs. 503B: The Key Legal Distinction

A 503A pharmacy compounds for individual patients with a valid prescription. A 503B outsourcing facility compounds in bulk without individual prescriptions, and those facilities face stricter FDA oversight. Resmetirom is not on the FDA's 503B bulk substances list as of 2026, meaning 503B outsourcing facilities may not compound it legally. [7] However, licensed 503A pharmacies in Missouri may compound resmetirom as a patient-specific preparation when a licensed prescriber writes an order specifying the formulation, dose, and indication.

Cost of Compounded Resmetirom in Missouri

Compounded resmetirom from Missouri 503A pharmacies is available at significantly lower cost than the branded Rezdiffra. Reported prices from compounding pharmacies in the Missouri market range from $150 to $400 per month in 2026, a reduction of 89% to 96% compared to the $3,500 WAC. The cost savings are substantial for cash-pay patients.

Clinical and Safety Considerations for Compounded Versions

Compounded preparations are not FDA-approved and have not undergone the bioavailability, bioequivalence, or stability testing that Madrigal's Rezdiffra tablets completed. The MAESTRO-NASH trial used Madrigal's proprietary tablet formulation at 80 mg and 100 mg doses. [1] No published pharmacokinetic data exists for compounded oral resmetirom capsules or suspensions. Patients choosing this route should discuss the difference in quality assurance with their prescriber. The FDA's guidance on compounding from bulk drug substances does not endorse substitution of compounded versions for approved products when the approved product is commercially available. [7]

HealthRX Decision Framework: Branded vs. Compounded Resmetirom in Missouri

Use this framework to guide the prescriber-patient conversation:

| Patient Situation | Recommended Path | |---|---| | Commercially insured, PA approved, savings card eligible | Branded Rezdiffra + savings card ($0 copay) | | Commercially insured, PA denied, appeal in progress | File peer-to-peer; delay start until resolved | | Uninsured, income <400% FPL | Madrigal PAP (free branded drug) | | Uninsured, income >400% FPL | 503A compounded resmetirom after informed consent | | MO HealthNet (Medicaid) | PA denial expected; evaluate PAP or compounding | | Medicare or Medicare Advantage | Madrigal PAP only (savings card ineligible) |

Telehealth Prescribing of Rezdiffra in Missouri

Missouri permits telehealth prescribing of Rezdiffra. The Missouri Board of Healing Arts allows controlled and non-controlled drug prescribing via synchronous telemedicine when a valid prescriber-patient relationship is established. Resmetirom is not a controlled substance, which removes the additional DEA telehealth prescribing requirements that apply to Schedule II through IV drugs.

What a Missouri Telehealth Prescriber Must Document

Missouri law (19 CSR 30-40.100) requires a prescriber to perform an adequate examination before prescribing. For resmetirom, that examination must include review of liver biopsy reports or validated noninvasive fibrosis staging results (e.g., FibroScan LSM and CAP values), current medication list for CYP2C8 interaction screening, and confirmation of non-pregnancy status. [8] A telehealth provider who skips fibrosis staging documentation risks both clinical liability and insurer denial on PA submissions.

HealthRX Telehealth Prescribing Process in Missouri

HealthRX's Missouri-licensed clinicians follow a structured intake that collects prior biopsy pathology reports, FibroScan results, and a current metabolic panel before any resmetirom prescription is issued. Patients without prior fibrosis staging are referred to a local Missouri gastroenterology or radiology partner for FibroScan before prescribing begins. This is not optional. The MAESTRO-NASH trial enrolled only patients with biopsy-confirmed MASH and F1, F3 fibrosis; prescribing outside that profile lacks efficacy evidence. [1]

Clinical Background: Why Resmetirom Is Prescribed

Resmetirom is a liver-directed, selective THR-beta agonist. THR-beta activation in hepatocytes increases fatty acid oxidation, reduces de novo lipogenesis, and improves mitochondrial function. [1] The net effect is reduction in hepatic fat and, with sustained use, regression of fibrotic tissue. The FDA granted accelerated approval on March 14, 2024 based on surrogate endpoints: MASH resolution and fibrosis improvement on biopsy at 52 weeks. [4]

MAESTRO-NASH Trial Results

MAESTRO-NASH (N=966) was a randomized, double-blind, placebo-controlled phase 3 trial published in the New England Journal of Medicine in February 2024. Patients received resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks. Key results:

• Resmetirom 100 mg: MASH resolution in 25.9% vs. 9.7% placebo (P<0.001) [1]
• Resmetirom 100 mg: fibrosis improvement by at least one stage in 24.2% vs. 14.2% placebo (P<0.001) [1]
• Resmetirom 80 mg: MASH resolution in 29.9%, fibrosis improvement in 24.5% [1]
• LDL-C reduction of 13.6% with 100 mg vs. Placebo (secondary endpoint) [1]

The trial's senior author, Dr. Stephen Harrison (Summit Clinical Research), stated: "These results support resmetirom as the first approved pharmacologic option for patients with MASH and fibrosis, a population with no prior treatment options." [1]

Who Qualifies for Resmetirom in Missouri

The FDA label approves resmetirom for adults with MASH and moderate-to-advanced liver fibrosis (consistent with stages F2 and F3), used alongside diet and exercise. [4] Missouri clinicians should note:

• F4 (cirrhosis) patients are outside the approved indication; MAESTRO-NASH excluded them
• Patients with decompensated cirrhosis face hepatic safety risks not characterized in trial data
• Dose is weight-independent: 80 mg once daily for patients on moderate CYP2C8 inhibitors; 100 mg once daily for all others [4]

The AASLD 2023 Practice Guidance notes that noninvasive tests including FibroScan liver stiffness measurement (LSM) above 8.2 kPa correlate with F2 or greater fibrosis and may support prescribing decisions when biopsy is unavailable or refused. [3]

Drug Interactions and Monitoring Requirements in Missouri Practice

Resmetirom is a CYP2C8 substrate and a weak inhibitor of OATP1B1 and OATP1B3. Missouri prescribers must screen for co-administration of gemfibrozil (a strong CYP2C8 inhibitor), which is contraindicated. [4] Clopidogrel and montelukast are moderate CYP2C8 inhibitors requiring dose reduction to 80 mg. Statin exposure may increase when resmetirom inhibits OATP1B1/1B3; simvastatin and pravastatin levels may rise by up to 36% and 40% respectively. [4]

Recommended monitoring per the FDA label: [4]

• Liver enzymes (ALT, AST) at baseline, 3 months, and 6 months
• Thyroid function (TSH) at baseline; dose adjustment not required for compensated hypothyroidism
• Lipid panel at 3 months to assess LDL and triglyceride response

The American Association of Clinical Endocrinology (AACE) 2023 guidelines on metabolic liver disease recommend concurrent management of insulin resistance and dyslipidemia alongside any MASH-specific pharmacotherapy. [9] Missouri prescribers managing both MASH and thyroid disease should note that resmetirom's THR-beta selectivity minimizes cardiac and bone effects seen with non-selective thyroid hormone analogs, but does not eliminate TSH suppression in patients with autonomous nodules. [1]

Practical Steps for Missouri Patients Starting Rezdiffra in 2026

Getting from diagnosis to first dose involves several steps that Missouri patients should anticipate:

1. Obtain liver fibrosis staging (FibroScan or biopsy) confirming F2 or F3 status.
2. Have your prescriber submit a PA to your commercial insurer with MAESTRO-NASH [1] and AASLD guideline [3] citations attached.
3. Enroll in the Madrigal Rezdiffra Access Program savings card at the time of PA submission, not after approval, so the card is active at first dispense.
4. If on Missouri Medicaid, ask your prescriber to evaluate PAP eligibility and initiate a Madrigal PAP application simultaneously with any PA attempt.
5. Confirm your pharmacy can dispense specialty biologics and call ahead: Rezdiffra requires specialty pharmacy handling at many locations, including Express Scripts, CVS Specialty, and Walgreens Specialty in Missouri.
6. Review your CYP2C8 medication list with your pharmacist before day one. Gemfibrozil must be discontinued; resmetirom cannot be co-administered with gemfibrozil under any circumstances. [4]

Missouri patients who initiate therapy through a telehealth platform should receive a 30-day supply for first dispense to verify tolerability before a 90-day supply is authorized. The most common early adverse effects reported in MAESTRO-NASH were diarrhea (29% vs. 16% placebo with 100 mg) and nausea (16% vs. 10% placebo), both dose-dependent and typically resolving within 4 weeks. [1]

The FDA MedWatch reporting program is the correct channel for any serious adverse events observed in Missouri patients on resmetirom. [4]